Stock Events

Stock Events

Autolus Therapeutics 

$1.4500
77
-$0.03-2.03% 20:00 Today
+$0.00+0%21:26After hours

Statistics

Day High
1.515
Day Low
1.4
52W High
2.7
52W Low
1.175
Volume
2,999,118
Avg. Volume
1,384,113
Mkt Cap
385.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

12AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.45
-0.32
-0.18
-0.05
Expected EPS
-0.24
Actual EPS
-0.18

Financials

-381.4%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
75.39MRevenue
-287.53MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AUTL. It's not an investment recommendation.
NVIDIA
7
NVDA
Microsoft
6
MSFT
Tesla
6
TSLA
AMD
6
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy, making it a direct competitor in the oncology treatment market.
Novartis
NVS
Mkt Cap293.94B
Novartis is a major player in the CAR-T space with approved therapies, competing in the same advanced cancer treatment market as Autolus.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to CAR-T therapy, making it a competitor in the gene therapy market.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, which are off-the-shelf, directly competing with Autolus' personalized approach.
Precigen
PGEN
Mkt Cap1.9B
Precigen focuses on next-generation gene and cell therapies, including CAR-T, making it a competitor in the advanced therapeutic space.

About

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Show more...
CEO
Dr. Christian Martin Itin Ph.D.
Employees
752
Country
United Kingdom
ISIN
US05280R1005

Listings

STU
DE
6A3A.STU
BOATS
BOATS
AUTL.BOATS
MU
DE
6A3A.MU
XNAS
US
AUTL

0 Comments

Share your thoughts

FAQ

What is Autolus Therapeutics stock price today?▼
The current price of AUTL is $1.45 USD — it has decreased by -2.03% in the past 24 hours. Watch Autolus Therapeutics stock price performance more closely on the chart.
What is Autolus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Autolus Therapeutics stocks are traded under the ticker AUTL.
Is Autolus Therapeutics stock price growing?▼
AUTL stock has fallen by -9.94% compared to the previous week, the month change is a -7.05% fall, over the last year Autolus Therapeutics has showed a -45.28% decrease.
What is Autolus Therapeutics market cap?▼
Today Autolus Therapeutics has the market capitalization of 385.91M
What were Autolus Therapeutics earnings last quarter?▼
AUTL earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.24 USD resulting in a +25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Autolus Therapeutics revenue for the last year?▼
Autolus Therapeutics revenue for the last year amounts to 75.39M USD.
What is Autolus Therapeutics net income for the last year?▼
AUTL net income for the last year is -287.53M USD.
How many employees does Autolus Therapeutics have?▼
As of July 14, 2026, the company has 752 employees.
In which sector is Autolus Therapeutics located?▼
Autolus Therapeutics operates in the Health & Wellness sector.
When did Autolus Therapeutics complete a stock split?▼
Autolus Therapeutics has not had any recent stock splits.
Where is Autolus Therapeutics headquartered?▼
Autolus Therapeutics is headquartered in London, United Kingdom.